Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX‐LCH Study): INPHOG‐HIST‐19‐03 (CTRI/2020/07/026937)
LENDEX is well tolerated and effective in 73% children with relapsed/refractory LCH. Future studies would include nine cycles of LENDEX followed by maintenance for 12 months with 6-mercaptopurine.
Authors
- Manas Kalra (ORCID: https://orcid.org/0000-0003-2570-7750)
- Satyendra Katewa
- Sirisharani Siddaiahgari
- Chetan Dhamne (ORCID: https://orcid.org/0000-0002-3637-2880)
- Revathi Raj
- Ramya Uppuluri
- Vinod Gunasekaran
- Nita Radhakrishnan
Institutions
- Apollo Hospitals (IN)
- Homi Bhabha National Institute (IN)
- Sir Ganga Ram Hospital (IN)
- Trichur Heart Hospital (IN)
- Institute of Child Health (IN)
- Rainbow Children's Hospital (IN)
- Manipal Hospital (IN)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1002/1545-5017.70217
- Primary Topic
- Histiocytic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00